Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) EBT (2020 - 2023)

Terns Pharmaceuticals' EBT history spans 4 years, with the latest figure at -$21.0 million for Q4 2023.

  • For Q4 2023, EBT fell 35.26% year-over-year to -$21.0 million; the TTM value through Dec 2023 reached -$90.0 million, down 49.98%, while the annual FY2025 figure was $841000.0, 100.94% up from the prior year.
  • EBT reached -$21.0 million in Q4 2023 per TERN's latest filing, up from -$29.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $31.7 million in Q4 2020 to a low of -$29.7 million in Q3 2023.
  • Average EBT over 4 years is -$12.4 million, with a median of -$13.8 million recorded in 2021.
  • The largest YoY upside for EBT was 2.84% in 2021 against a maximum downside of 143.81% in 2021.
  • A 4-year view of EBT shows it stood at $31.7 million in 2020, then plummeted by 143.81% to -$13.9 million in 2021, then fell by 11.57% to -$15.5 million in 2022, then plummeted by 35.26% to -$21.0 million in 2023.
  • Per Business Quant, the three most recent readings for TERN's EBT are -$21.0 million (Q4 2023), -$29.7 million (Q3 2023), and -$17.8 million (Q2 2023).